Lambert-Eaton Myasthenic Syndrome (LEMS) - Epidemiology Forecast to 2030

DelveInsight’s ‘Lambert–Eaton Myasthenic Syndrome (LEMS) - Epidemiology Forecast - 2030’ report delivers an in-depth understanding of the LEMS, historical and forecasted epidemiology as well as the LEMS trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.
Lambert–Eaton Myasthenic Syndrome (LEMS) Disease Understanding
Lambert–Eaton myasthenic syndrome (LEMS) is an autoimmune disease in which the immune system attacks the body's own tissues. The attack occurs at the connection between nerve and muscle (the neuromuscular junction) and interferes with the ability of nerve cells to send signals to muscle cells. Specifically, the immune system attacks the calcium channels on nerve endings that are required to trigger the release of chemicals (acetylcholine). With fewer calcium channels, the nerve ending releases less acetylcholine. Acetylcholine is a chemical messenger that triggers muscle contraction. In people with LEMS, the lowered levels of acetylcholine are not sufficient to cause normal muscle contractions, causing muscle weakness. The disease is named for Edward Lambert and Lee Eaton, neurologists at the Mayo Clinic in Rochester, Minn., who first described the myasthenic syndrome in the 1950s and 1960s.
There are two types of LEMS, paraneoplastic, in which the disease is associated with cancer and non-paraneoplastic with no known underlying cause.
Lambert–Eaton Myasthenic Syndrome (LEMS) Epidemiology Perspective by DelveInsight
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Total Prevalent Cases of LEMS, Total Diagnosed Prevalent Cases of LEMS, Gender-specific Diagnosed Prevalent Cases of LEMS, Type-specific Diagnosed Prevalent Cases of LEMS, and Diagnosed Prevalent Cases of LEMS by Malignancy scenario of LEMS in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom) and Japan from 2017 to 2030.
Lambert–Eaton Myasthenic Syndrome (LEMS) Detailed Epidemiology Segmentation
• Total prevalent cases of LEMS in the 7MM was found to be 5,977 in 2017.
• Based on the etiology, LEMS is divided into two types; paraneoplastic and idiopathic. There were a total 1,978 diagnosed prevalent cases of LEMS in the United States in 2017, out of which 1,154 accounted for paraneoplastic and 824 cases accounted for idiopathic.
• As per the assessments, in the 7MM, the majority of cases of LEMS are paraneoplastic form as compared to idiopathic form.
• Among the two forms of LEMS, the paraneoplastic form constitutes more than half of the cases and is mostly associated with intrathoracic neoplasms. Most of the cases were seen with small cell lung cancer (SCLC); other subtypes of lung cancer are extremely rare.
• Among the EU-5 countries, Germany witnessed the highest prevalent population accounting for 6.93% of the total prevalent cases in 7MM, followed by France and the United Kingdom. On the other hand, Spain witnessed the lowest number of prevalent cases in 2017.
• Japan was assessed with 21.32% of the total prevalent population, with 1,274 cases observed in 2017.
Scope of the Report
• The report covers the descriptive overview of LEMS, explaining its causes, signs and symptoms, complications, clinical aspects, and pathophysiology.
• The report provides insight into the 7MM historical and forecasted patient pool covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom) and Japan.
• The report assesses the disease risk and burden and highlights the unmet needs of LEMS.
• The report helps to recognize the growth opportunities in the 7MM with respect to the patient population.
• The report provides the segmentation of the disease epidemiology for 7MM by Total Prevalent Cases of LEMS, Total Diagnosed Prevalent Cases of LEMS, Gender-specific Diagnosed Prevalent Cases of LEMS, Type-specific Diagnosed Prevalent Cases of LEMS, and Diagnosed Prevalent Cases of LEMS by Malignancy.

Report Highlights
• 11-Year Forecast of LEMS
• 7MM Coverage
• Total Prevalent Cases of LEMS
• Total Diagnosed Prevalent Cases of LEMS
• Gender-specific Diagnosed Prevalent Cases of LEMS
• Type-specific Diagnosed Prevalent Cases of LEMS
• Diagnosed Prevalent Cases of LEMS by Malignancy
Key Questions Answered
• What is the disease risk, burden and unmet needs of LEMS?
• What is the historical LEMS patient pool in the United States, EU5 (Germany, France, Italy, Spain, and the UK) and Japan?
• What would be the forecasted patient pool of LEMS at the 7MM level?
• What will be the growth opportunities across the 7MM with respect to the patient population pertaining to LEMS?
• Out of the above-mentioned countries, which country would have the highest prevalent population of LEMS during the forecast period (2020–2030)?
• At what CAGR the population is expected to grow across the 7MM during the forecast period (2020–2030)?
Reasons to buy
The LEMS report will allow the user to -
• Develop business strategies by understanding the trends shaping and driving the 7MM LEMS epidemiology forecast.
• The LEMS epidemiology report and model were written and developed by Masters and Ph.D. level epidemiologists.
• The LEMS epidemiology model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over the eleven-year forecast period using reputable sources.
Key Assessments
• Patient Segmentation
• Disease Risk and Burden
• Risk of disease by the segmentation
• Factors driving growth in a specific patient population
Geographies Covered
• The United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan
Study Period: 2017–2030


1 Key Insights
2. Executive Summary
3. Lambert–Eaton Myasthenic Syndrome (LEMS): Disease Overview
3.1. Introduction
3.2. Signs and Symptoms
3.3. Cause of Lambert–Eaton Myasthenic Syndrome
3.4. Risk Factors
3.5. Pathophysiology Lambert–Eaton Myasthenic Syndrome
3.6. Pathogenesis
3.7. Clinical Manifestations
3.8. Diagnosis
3.9. Diagnostic Algorithm
4. Epidemiology and Patient Population
4.1. Epidemiology Methodology
4.2. Key Findings
4.3. Total Prevalent Cases of Lambert–Eaton Myasthenic Syndrome (LEMS) in the 7MM
4.4. Total Diagnosed Prevalent Cases of Lambert–Eaton Myasthenic Syndrome (LEMS) in the 7MM
5. United States Epidemiology
5.1. Assumptions and Rationale
5.2. Total Prevalent Cases of Lambert-Eaton Myasthenic Syndrome (LEMS) in the United States
5.3. Total Diagnosed Prevalent Cases of Lambert-Eaton Myasthenic Syndrome (LEMS) in the United States
5.4. Gender-specific Diagnosed Prevalent Cases of Lambert-Eaton Myasthenic Syndrome (LEMS) in the United States
5.5. Type-specific Diagnosed Prevalent Cases of Lambert-Eaton Myasthenic Syndrome (LEMS) in the United States
5.6. Diagnosed Prevalent Cases of Lambert-Eaton Myasthenic Syndrome (LEMS) by Malignancy in the United States
6. EU-5 Epidemiology
6.1. Germany
6.1.1. Total Prevalent Cases of Lambert-Eaton Myasthenic Syndrome (LEMS) in Germany
6.1.2. Total Diagnosed Prevalent Cases of Lambert-Eaton Myasthenic Syndrome (LEMS) in Germany
6.1.3. Gender-specific Diagnosed Prevalent Cases of Lambert-Eaton Myasthenic Syndrome (LEMS) in Germany
6.1.4. Type-specific Diagnosed Prevalent Cases of Lambert-Eaton Myasthenic Syndrome (LEMS) in Germany
6.1.5. Diagnosed Prevalent Cases of Lambert-Eaton Myasthenic Syndrome (LEMS) by Malignancy in Germany
6.2. France
6.2.1. Total Prevalent Cases of Lambert-Eaton Myasthenic Syndrome (LEMS) in France
6.2.2. Total Diagnosed Prevalent Cases of Lambert-Eaton Myasthenic Syndrome (LEMS) in France
6.2.3. Gender-specific Prevalent Cases of Lambert-Eaton Myasthenic Syndrome (LEMS) in France
6.2.4. Type-specific Diagnosed Prevalent Cases of Lambert-Eaton Myasthenic Syndrome (LEMS) in France
6.2.5. Diagnosed Prevalent Cases of Lambert-Eaton Myasthenic Syndrome (LEMS) by Malignancy in France
6.3. Italy
6.3.1. Total Prevalent Cases of Lambert-Eaton Myasthenic Syndrome (LEMS) in Italy
6.3.2. Total Diagnosed Prevalent Cases of Lambert-Eaton Myasthenic Syndrome (LEMS) in Italy
6.3.3. Gender-specific Diagnosed Prevalent Cases of Lambert-Eaton Myasthenic Syndrome (LEMS) in Italy
6.3.4. Type-specific Diagnosed Prevalent Cases of Lambert-Eaton Myasthenic Syndrome (LEMS) in Italy
6.3.5. Diagnosed Prevalent Cases of Lambert-Eaton Myasthenic Syndrome (LEMS) by Malignancy in Italy
6.4. Spain
6.4.1. Total Prevalent Cases of Lambert-Eaton Myasthenic Syndrome (LEMS) in Spain
6.4.2. Total Diagnosed Prevalent Cases of Lambert-Eaton Myasthenic Syndrome (LEMS) in Spain
6.4.3. Gender-specific Diagnosed Prevalent Cases of Lambert-Eaton Myasthenic Syndrome (LEMS) in Spain
6.4.4. Type-specific Diagnosed Prevalent Cases of Lambert-Eaton Myasthenic Syndrome (LEMS) in Spain
6.4.5. Diagnosed Prevalent Cases of Lambert-Eaton Myasthenic Syndrome (LEMS) by Malignancy in Spain
6.5. United Kingdom
6.5.1. Total Prevalent Cases of Lambert-Eaton Myasthenic Syndrome (LEMS) in the United Kingdom
6.5.2. Total Diagnosed Prevalent Cases of Lambert-Eaton Myasthenic Syndrome (LEMS) in the United Kingdom
6.5.3. Gender-specific Diagnosed Prevalent Cases of LEMS in the United Kingdom
6.5.4. Type-specific Diagnosed Prevalent Cases of LEMS in the United Kingdom
6.5.5. Diagnosed Prevalent Cases of LEMS by Malignancy in the United Kingdom
7. Japan Epidemiology
7.1. Assumptions and Rationale
7.2. Total Prevalent Cases of Lambert-Eaton Myasthenic Syndrome (LEMS) in Japan
7.3. Total Diagnosed Prevalent Cases of Lambert-Eaton Myasthenic Syndrome (LEMS) in Japan
7.4. Gender-specific Diagnosed Prevalent Cases of Lambert-Eaton Myasthenic Syndrome (LEMS) in Japan
7.5. Type-specific Diagnosed Prevalent Cases of Lambert-Eaton Myasthenic Syndrome (LEMS) in Japan
7.6. Diagnosed Prevalent Cases of Lambert-Eaton Myasthenic Syndrome (LEMS) by Malignancy in Japan
8. Appendix
8.1. Report Methodology
9. DelveInsight Capabilities
10. Disclaimer
11. About DelveInsight
Table 1 Summary of LEMS Epidemiology, and Key Events (2017–2030)
Table 2 Signs and Symptoms of LEMS
Table 3 Classification and characteristics of voltage‐gated calcium channels (VGCC)
Table 4 Total Prevalent Cases of LEMS in the 7MM (2017–2030)
Table 5 Total Diagnosed Prevalent Cases of LEMS in the 7MM (2017–2030)
Table 6 Total Prevalent Cases of LEMS in the United States (2017–2030)
Table 7 Total Diagnosed Prevalent Cases of LEMS in the United States (2017–2030)
Table 8 Gender-specific Diagnosed Prevalent Cases of LEMS in the United States (2017–2030)
Table 9 Type-specific Diagnosed Prevalent Cases of LEMS in the United States (2017–2030)
Table 10 Diagnosed Prevalent Cases of LEMS by Malignancy in the United States (2017–2030)
Table 11 Total Prevalent Cases of LEMS in Germany (2017–2030)
Table 12 Total Diagnosed Prevalent Cases of LEMS in Germany (2017–2030)
Table 13 Gender-specific Diagnosed Prevalent Cases of LEMS in Germany (2017–2030)
Table 14 Type-specific Diagnosed Prevalent Cases of LEMS in Germany (2017–2030)
Table 15 Diagnosed Prevalent Cases of LEMS by Malignancy in Germany (2017–2030)
Table 16 Total Prevalent Cases of LEMS in France (2017–2030)
Table 17 Total Diagnosed Prevalent Cases of LEMS in France (2017–2030)
Table 18 Gender-specific Diagnosed Prevalent Cases of LEMS in France (2017–2030)
Table 19 Type-specific Diagnosed Prevalent Cases of LEMS in France (2017–2030)
Table 20 Diagnosed Prevalent Cases of LEMS by Malignancy in France (2017–2030)
Table 21 Total Prevalent Cases of LEMS in Italy (2017–2030)
Table 22 Total Diagnosed Prevalent Cases of LEMS in Italy (2017–2030)
Table 23 Gender-specific Diagnosed Prevalent Cases of LEMS in Italy (2017–2030)
Table 24 Type-specific Diagnosed Prevalent Cases of LEMS in Italy (2017–2030)
Table 25 Diagnosed Prevalent Cases of LEMS by Malignancy in Italy (2017–2030)
Table 26 Total Prevalent Cases of LEMS in Spain (2017–2030)
Table 27 Total Diagnosed Prevalent Cases of LEMS in Spain (2017–2030)
Table 28 Gender-specific Diagnosed Prevalent Cases of LEMS in Spain (2017–2030)
Table 29 Type-specific Diagnosed Prevalent Cases of LEMS in Spain (2017–2030)
Table 30 Diagnosed Prevalent Cases of LEMS by Malignancy in Spain (2017–2030)
Table 31 Total Prevalent Cases of LEMS in the United Kingdom (2017–2030)
Table 32 Total Diagnosed Prevalent Cases of LEMS in the United Kingdom (2017–2030)
Table 33 Gender-specific Diagnosed Prevalent Cases of LEMS in the United Kingdom (2017–2030)
Table 34 Type-specific Diagnosed Prevalent Cases of LEMS in the United Kingdom (2017–2030)
Table 35 Diagnosed Prevalent Cases of LEMS by Malignancy in the United Kingdom (2017–2030)
Table 36 Total Prevalent Cases of LEMS in Japan (2017–2030)
Table 37 Total Diagnosed Prevalent Cases of LEMS in Japan (2017–2030)
Table 38 Gender-specific Diagnosed Prevalent Cases of LEMS in Japan (2017–2030)
Table 39 Type-specific Diagnosed Prevalent Cases of LEMS in Japan (2017–2030)
Table 40 Diagnosed Prevalent Cases of LEMS by Malignancy in Japan (2017–2030)
Figure 1 Signs and Symptoms of LEMS
Figure 2 Lambert and colleague’s classical description of the clinical features
Figure 3 Mechanism of Action
Figure 4 Pathophysiology of LEMS
Figure 5 Diagnostic Algorithm
Figure 6 LEMS diagnosis and oncological screening algorithm
Figure 7 Diagnostic Algorithm of LEMS
Figure 8 Diagnostic algorithm for clinically suspected LEMS
Figure 9 Total Prevalent Cases of LEMS in the 7MM (2017–2030)
Figure 10 Total Diagnosed Prevalent Cases of LEMS in the 7MM (2017–2030)
Figure 11 Total Prevalent Cases of LEMS in the United States (2017–2030)
Figure 12 Total Diagnosed Prevalent Cases of LEMS in the United States (2017–2030)
Figure 13 Gender-specific Diagnosed Prevalent Cases of LEMS in the United States (2017–2030)
Figure 14 Type-specific Diagnosed Prevalent Cases of LEMS in the United States (2017–2030)
Figure 15 Diagnosed Prevalent Cases of LEMS by Malignancy in the United States (2017–2030)
Figure 16 Total Prevalent Cases of LEMS in Germany (2017–2030)
Figure 17 Total Diagnosed Prevalent Cases of LEMS in Germany (2017–2030)
Figure 18 Gender-specific Diagnosed Prevalent Cases of LEMS in Germany (2017–2030)
Figure 19 Type-specific Diagnosed Prevalent Cases of LEMS in Germany (2017–2030)
Figure 20 Diagnosed Prevalent Cases of LEMS by Malignancy in Germany (2017–2030)
Figure 21 Total Prevalent Cases of LEMS in France (2017–2030)
Figure 22 Total Diagnosed Prevalent Cases of LEMS in France (2017–2030)
Figure 23 Gender-specific Diagnosed Prevalent Cases of LEMS in France (2017–2030)
Figure 24 Type-specific Diagnosed Prevalent Cases of LEMS in France (2017–2030)
Figure 25 Diagnosed Prevalent Cases of LEMS by Malignancy in France (2017–2030)
Figure 26 Total Prevalent Cases of LEMS in Italy (2017–2030)
Figure 27 Total Diagnosed Prevalent Cases of LEMS in Italy (2017–2030)
Figure 28 Gender-specific Diagnosed Prevalent Cases of LEMS in Italy (2017–2030)
Figure 29 Type-specific Diagnosed Prevalent Cases of LEMS in Italy (2017–2030)
Figure 30 Diagnosed Prevalent Cases of LEMS by Malignancy in Italy (2017–2030)
Figure 31 Total Prevalent Cases of LEMS in Spain (2017–2030)
Figure 32 Total Diagnosed Prevalent Cases of LEMS in Spain (2017–2030)
Figure 33 Gender-specific Diagnosed Prevalent Cases of LEMS in Spain (2017–2030)
Figure 34 Type-specific Diagnosed Prevalent Cases of LEMS in Spain (2017–2030)
Figure 35 Diagnosed Prevalent Cases of LEMS by Malignancy in Spain (2017–2030)
Figure 36 Total Prevalent Cases of LEMS in the United Kingdom (2017–2030)
Figure 37 Total Diagnosed Prevalent Cases of LEMS in the United Kingdom (2017–2030)
Figure 38 Gender-specific Diagnosed Prevalent Cases of LEMS in the United Kingdom (2017–2030)
Figure 39 Type-specific Diagnosed Prevalent Cases of LEMS in the United Kingdom (2017–2030)
Figure 40 Diagnosed Prevalent Cases of LEMS by Malignancy in the United Kingdom (2017–2030)
Figure 41 Total Prevalent Cases of LEMS in Japan (2017–2030)
Figure 42 Total Diagnosed Prevalent Cases of LEMS in Japan (2017–2030)
Figure 43 Gender-specific Diagnosed Prevalent Cases of LEMS in Japan (2017–2030)
Figure 44 Type-specific Diagnosed Prevalent Cases of LEMS in Japan (2017–2030)
Figure 45 Diagnosed Prevalent Cases of LEMS by Malignancy in Japan (2017–2030)

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook